Campbell & CO Investment Adviser LLC Takes Position in Amicus Therapeutics, Inc. $FOLD

Campbell & CO Investment Adviser LLC purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 656,111 shares of the biopharmaceutical company’s stock, valued at approximately $3,760,000. Campbell & CO Investment Adviser LLC owned 0.21% of Amicus Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of FOLD. Strs Ohio purchased a new position in shares of Amicus Therapeutics in the 1st quarter valued at about $30,000. PNC Financial Services Group Inc. lifted its holdings in shares of Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Amicus Therapeutics during the first quarter worth approximately $53,000. CWM LLC increased its position in Amicus Therapeutics by 395.9% during the second quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 7,502 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new stake in Amicus Therapeutics in the second quarter valued at approximately $64,000.

Insider Activity at Amicus Therapeutics

In related news, insider David Michael Clark sold 25,643 shares of the stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $9.51, for a total value of $243,864.93. Following the sale, the insider directly owned 322,618 shares of the company’s stock, valued at approximately $3,068,097.18. This represents a 7.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

FOLD has been the topic of a number of recent research reports. Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. The Goldman Sachs Group increased their target price on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Wednesday. JPMorgan Chase & Co. raised their price target on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Amicus Therapeutics Price Performance

FOLD stock opened at $8.87 on Friday. The firm has a 50 day moving average of $8.30 and a 200-day moving average of $7.09. The company has a market cap of $2.74 billion, a price-to-earnings ratio of -73.91 and a beta of 0.66. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $11.36.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.Amicus Therapeutics’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the business posted $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.